Poliovirus vaccine-inactivated

Vaccines

Volumn , Issue , 2008, Pages 605-629

  Plotkin, Stanley A ^a   Vidor, Emmanuel ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85159000385     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50029-5     Document Type: Chapter

References (234)

1. AS Monto (1999) Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. Epidemiol Rev 21 7-23.
2. SM Lambert and H Markel (2000) Making history: Thomas Francis, Jr, MD, and the 1954 Salk Poliomyelitis Vaccine Field Trial. Arch Pediatr Adolesc Med 154 512-517.
3. SA Plotkin (1993) An end to Manicheism. Public Health Rev 21 135-138.
4. J Gear (1996) The history of the poliomyelitis Research Foundation Rivonia, South Africa: Poliomyelitis Research Foundation 4-13.
5. D Bodian, I Morgan and H Howe (1949) Differentiation of types of poliomyelitis viruses; the grouping of fourteen strains into three basic immunologic types. Am J Hyg 49 234-245.
6. DM Horstman, R McCollum and A Mascola (1954) Viremia in human poliomyelitis. J Experimental Med 99 355-369.
7. W Hammon, LL Coriell, PF Wehrle and J Stokes Jr (1953) Evaluation of red cross gamma globulin as a prophylactic agent for poliomyleitis. JAMA 151 1272-1285.
8. J Enders, T Weller and F Robbins (1949) Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109 85-87.
9. DS Burke (2004) Lessons learned from the 1954 Field Trial of Poliomyelitis Vaccine. Clin Trials 1 3-5.
10. J Beale (1996) The development of IPV Paris: Elsevier
11. AL van Wezel (1967) Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 216 64-65.
12. B Montagnon (1988) Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 70 27-47.
13. JR Paul, PJ Melnick, V Barnett and N Goldblum (1952) A survey of neutralizing antibodies to poliomyelitis in Cairo, Egypt. Am J Hyg 55 402-413.
14. A Lebrun, J Cerf, H Gelfand and B Fantini (1960) Vaccination with the CHAT strain of type I attenuated poliomyelitis virus in Leopoldville, Belgian Congo. I. Description of the city, its history of poliomyelitis, and the plan of vaccination campaign. Bull World Health Org 22 203-213.
15. PD Minor (1990) Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 161 121-154.
16. S Plotkin, H Koprowski and J Stokes Jr (1960) Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 23 1041-1062.
17. M Brodie and W Park (1936) Active immunization against poliomyelitis. Am J Public Health 26 119-125.
18. J Kolmer (1936) Vaccination against acute anterior poliomyelitis. Am J Public Health 26 126-135.
19. G Kersten, T Hazendonk and C Beuvery (1999) Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17 2059-2066.
20. R Murray (1961) Standardization licensing and availability of live polio virus vaccine. JAMA 175 843-846.
21. S Berkovich, J Pickering and S Kibrick (1959) Paralytic poliomyelitis in Massachusetts. N Eng J MEd 264 1325-1329.
22. BJ Montagnon, B Fanget and JC Vincent-Falquet (1984) Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 6(S2), S341-S344.
23. M Duchene, J Peetermans, E D'Hont, et al. (1990) Production of poliovirus vaccines: past, present, and future. Viral Immunol 3 243-272.
24. BJ Montagnon, JC Vincent-Falquet and JF Saluzzo (1999) Experience with vero cells at Pasteur Merieux Connaught. Dev Biol Stand 98 137-140.
25. F Horaud (1995) Viral vaccines and residual cellular DNA. Biologicals 23 225-228.
26. JL Melnick (1990) Virus inactivation: lessons from the past. Dev Biol Stand 75 29-36.
27. B Meignier (2001) Industrial experience with live polio vaccine prepared on the Vero continuous cell line. Dev Biol (Basel) 106 341-342.
28. DJ Wood and AB Heath (1995) A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals 23 301-311.
29. DJ Wood, AB Heath, GF Kersten, et al. (1997) A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine. Biologicals 25 59-64.
30. G Rezapkin, E Dragunsky and K Chumakov (2005) Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV). Biologicals 33 17-27.
31. VR Racaniello (2006) One hundred years of poliovirus pathogenesis. Virology 344 9-16.
32. J Martin, G Crossland, DJ Wood and PD Minor (2003) Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen. Virol 84 1781-1788.
33. EM Dragunsky, AP Ivanov, VR Wells, AV Ivshina, et al. (2004) Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 190 1404-1412.
34. H Kreeftenberg, T van der Velden, G Kersten, et al. (2006) Technology transfer of Sabin-IPV to new developing country markets. Biologicals 34(2), 155-158.
35. G Rezapkin, J Martin and K Chumakov (2005) Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 33 29-39.
36. E Dragunsky, Y Chernokhvostova, R Taffs, et al. (1997) Tg PVR21 mice for testing type-3 oral poliovirus vaccines: role of clinical observation and histological examination. Vaccine 15 1863-1866.
37. G Kersten, T Hazendonk and C Beuvery (1999) Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17 2059-2066.
38. LA Sawyer, D Wood, M Ferguson, et al. (1997) Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site. Biologicals 25 299-306.
39. DJ Wood, AB Heath and LA Sawyer (1995) A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals 23 83-94.
40. JR Murph, C Grose, P McAndrew, et al. (1988) Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 7 760-765.
41. Y Doi, S Abe, H Yamamoto, et al. (2001) Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 105 163-169.
42. H Horie, H Yoshida, K Matsuura, et al. (2002) Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 68 445-451.
43. M Ferguson, DJ Wood and PD Minor (1993) Antigenic structure od poliovirus in inactivated vaccines. J. Gen. Virol 74 685-690.
44. J Salk (1984) One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev Infect Dis 6(Suppl 2), S444–S450.
45. L Mellander, M Bottiger, LA Hanson, et al. (1993) Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Paediatr 82 552-556.
46. LA Sawyer, J McInnis, A Patel, et al. (1994) Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 12 851-856.
47. H Sormunen, M Stenvik, J Eskola and T Hovi (2001) Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol 63 305-310.
48. T Hovi (2001) Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 19 2268-2272.
49. J Singh, RN Ravi, AK Dutta, et al. (1992) Immunogenicity of enhanced potency inactivated polio vaccine. Indian Pediatr 29 1353-1356.
50. PW Kok, J Leeuwenburg, P Tukei, et al. (1992) Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ 70 93-103.
51. N Linder, R Handsher, B German, et al. (2000) Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed 83 F24-F27.
52. Combined immunization of infants with oral and inactivated poliovirus vaccines results of a randomized trial in The Gambia, Oman, and Thailand WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Bull World Health Organ 74 253-268.
53. RW Sutter, AJ Suleiman, PG Malankar, et al. (1997) Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. J Infect Dis 175(Suppl 1), S235–S240.
54. EA Simoes, B Padmini, MC Steinhoff, et al. (1985) Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 139 977-980.
55. EA Simoes and TJ John (1986) The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand 14 127-131.
56. TA Swartz, R Handsher, P Stoeckel, et al. (1989) Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 5 143-145.
57. T Hovi, M Stenvik and M Agboatwalla (1999) Effect of administering oral and inactivated polio vaccines immediately after birth. Eur J Clin Microbiol Infect Dis 18 526-528.
58. N Linder, M Yaron, R Handsher, et al. (1995) Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 127 128-130.
59. PK Jain, AK Dutta, S Nangia, et al. (1997) Seroconversion following killed polio vaccine in neonates. Indian J Pediatr 64 511-515.
60. E Vidor, P Caudrelier and SA Plotkin (1994) The place of DTP/eIPV vaccine in routine paediatric vaccination. Rev Med Virol 4 261-277.
61. JD Baker, SA Halperin, K Edwards, et al. (1992) Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 121 523-527.
62. SA Halperin, JM Langley and BJ Eastwood (1996) Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine. Clin Infect Dis 22 59-62.
63. SA Halperin, BJ Eastwood and JM Langley (1995) Immune responses to pertussis vaccines concurrently administered with viral vaccines. Ann NY Acad Sci 754 89-96.
64. S Kurikka, H Kayhty, L Saarinen, et al. (1996) Comparison of five different vaccination schedules with Haemophilus influenzae type β-tetanus toxoid conjugate vaccine. J Pediatr 128 524-530.
65. S Black and DP Greenberg (2005) A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 4 793-805.
66. F Zepp, M Knuf, U Heininger, et al. (2004) Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22 2226-2233.
67. E Grimprel, F von Sonnenburg, R Sanger, et al. (2005) Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 23 3657-3667.
68. Combined immunization of infants with oral and inactivated poliovirus vaccines results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. J Infect Dis 175(Suppl 1), S215–S227.
69. R Krishnan, M Jadhav and TJ John (1983) Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 61 689-692.
70. R Gylca, V Gylca, O Benes, et al. (2000) A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 19 825-833.
71. Desai AM. AvP study MAS01489. data in file. 1989.
72. S Nirmal, T Cherian, BU Samuel, et al. (1998) Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 16 928-931.
73. Hussey G, Malan H, Hughes J, et al. Aventis Pasteur Study HIT40. Data in file. 1998.
74. Capeding MR. Aventis Pasteur study EUV07199/HE9810. Data in File. 1999.
75. GH Dayan, M Thorley, Y Yamamura, et al. (2007) Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. JID 195 12-20.
76. Cuba IPV Study Collaborative Group (2007) Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 356(15), 1536-1544.
77. Eskola J, Dagan Aventis Pasteur study PNF06, data in file. 1997
78. ME Ramsay, NT Begg, J Gandhi and D Brown (1994) Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 13 1117-1121.
79. P Strebel, N Ion-Nedelcu, AL Baughman, et al. (1995) Intramuscular injections within 30 days of immunization with oral poliovirus vaccine–a risk factor for vaccine-associated paralytic poliomyelitis. New Eng J Med 332 500-506.
80. N Ion-Nedelcu, P Strebel, F Toma, et al. (1997) Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992–1994. J Infect Dis 175 S241-S246.
81. BJ Moriniere, FP van Loon, PH Rhodes, et al. (1993) Immunogenicity of a Supplemental dose of oral versus inactivated poliovirus vaccine [see comments]. Lancet 341 1545-1550.
82. SCA Adenyi-Jones, H Faden, MB Ferdon, et al. (1992) Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 120 686-689.
83. N Linder, M Yaron, R Handsher, et al. (1995) Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 127 128-130.
84. JP Sikora and D Chlebna-Sokol (2003) [Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants]. Przegl Lek 60 699-703.
85. TM O'Shea, RG Dillard, DC Gillis, et al. (1993) Low rate of response to enhanced inactivated polio vaccine in preterm infants with chronic illness. Clin Res & Reg Aff 10(1), 49-57.
86. M Barbi, M Bardare, C Luraschi, et al. (1992) Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers. Eur J Epidemiol 8 211-216.
87. D Varon, R Handsher, R Dardik, et al. (1993) Response of hemophilic patients to poliovirus vaccination: correlation with HIV serology and with immunological parameters. J Med Virol 40 91-95.
88. R Sipila, L Hortling and T Hovi (1990) Good seroresponse to enhanced-potency inactivated poliovirus vaccine in patients on chronic dialysis. Nephrol Dial Transplant 5 352-355.
89. D Engelhard, R Handsher, E Naparstek, et al. (1991) Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 8 295-300.
90. P Ljungman, V Duraj and L Magnius (1991) Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 7 89-93.
91. P Ljungman, J Aschan, B Gustafsson, et al. (2004) Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 34 1067-1069.
92. PL Ogra, D Karzon, F Righthand, et al. (1968) Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 279 893-900.
93. G Zhaori, M Sun, HS Faden and PL Ogra (1989) Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 159 1018-1024.
94. H Faden and L Duffy (1992) Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Amer J Dis Child 146 1320-1323.
95. IM Onorato, JF Modlin, AM McBean, et al. (1991) Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 163 1-6.
96. LA Hanson, B Carlsson, F Jalil, et al. (1984) Different secretory IgA antibody responses after immunization with inactivated and live poliovirus vaccines. Rev Infect Dis 6(Suppl 2), S356–S360.
97. JP Fox, HM Gelfand, DR LeBlanc, et al. (1958) The influence of natural and artifically induced immunity on alimentary infections with poliovirus. American Journal of Public Health 48(9), 1181-1192.
98. DM Horstman, JR Paul, JL Melnick and JV Deutsch (1957) Infection induced by oral administration of attenuated poliovirus to persons possing homotypic antibody. J Exper Med 105 159-177.
99. D David, M Lipson, D Carver, et al. (1958) The degree and duration of poliomyelitis virus excretion among vaccinated household contacts of clinical cases of poliomyelitis. Pediatrics 22 33-40.
100. HM Gelfand, DR LeBlanc, L Potash and JP Fox (1959) Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 70 312-327.
101. HA Howe, W O'Leary, W Bender, et al. (1956) Day-by-day response of vaccinated chimpanzees to poliomyelitis infection. Am J Public Health 47 871-875.
102. DE Craig and GC Brown (1959) The relationship between poliomyelitis antibody and virus excretion from the pharynx and anus of orally infected monkeys. Am J Hygiene 69(1), 1-12.
103. R Selvakumar and TJ John (1987) Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 5 141.
104. WM Marine, TDY Chin and CR Gravelle (1962) Limitation of fecal and pharyngeal poliovirus excretion in salk-vaccinated children. Am J Hyg 76 173-195.
105. Y Ghendon and SE Robertson (1994) Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 72 973-983.
106. PM Oostvogel, JK van Wijngaarden, HG van der Avoort, et al. (1994) Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–93. Lancet 344 665-670.
107. E Samoilovich, M Roivainen, LP Titov and T Hovi (2003) Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol 71 274-280.
108. L Piirainen, M Stenvik, M Roivainen, et al. (1999) Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. Vaccine 17 1084-1090.
109. I Parent du Chatelet, AT Merchant, S Fisher-Hoch, et al. (2003) Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 21(15), 1710-1718.
110. M Laassri, K Lottenbach, R Belshe, et al. (2005) Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 192 2092-2098.
111. PD Minor (1992) The molecular biology of poliovaccines. J Gen Virol 73 3065-3077.
112. AJ Macadam, C Arnold, J Howlett, et al. (1989) Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172 408-414.
113. KM Chumakov, LB Powers, KE Noonan, et al. (1991) Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A 88 199-203.
114. R Abraham, P Minor, G Dunn, et al. (1993) Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 168 1105-1109.
115. PL Ogra, HS Faden, R Abraham, et al. (1991) Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164 191-194.
116. AD Murdin, L Barreto and SA Plotkin (1996) Inactivated poliovirus vaccine: past and present experience. Vaccine 14 735-746.
117. PD Minor, G Dunn, ME Ramsay and D Brown (2005) Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 75 153-160.
118. M Laassri, K Lottenbach, R Belshe, et al. (2006) Analysis of reversions in the 5’-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis 193 1344-1349.
119. T Francis, R Korns, R Voight, et al. (1955) An evaluation of the 1954 poliomyelitis vaccine trials University of Michigan
120. JL Melnick, M Benyeh-Melnick, R Peña and M Yow (1961) Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis. JAMA 175 1159-1162.
121. P Stoeckel, M Schlumberger, G Parent, et al. (1984) Use of killed poliovirus vaccine in a routine immunization program in West Africa. Rev Infect Dis 6(S2), S463-S466.
122. Pasteur Merieux Connaught Laboratories (Aventis Pasteur). Poliovirus Vaccine Inactivated (IPOL) package insert. 1997.
123. CDC Paralytic poliomyelitis—Senegal, 1986–1987: Update on the N-IPV efficacy study. MMWR 37 257-259.
124. John T. Poliovirus vaccine and poliomyelitis control in India [abstract]. 1992. World Conference on Poliomyelitis and Measles, New Delhi.
125. PV Varughese, AO Carter, SE Acres and J Furesz (1989) Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can J Public Health 80 363-368.
126. TD Chin (1984) Immunity induced by inactivated poliovirus vaccine and excretion of virus. Rev Infect Dis 6(Suppl 2), S369–S370.
127. B Hofman (1967) Poliomyelitis in the Netherlands before and after vaccination with inactivated poliovaccine. J Hyg 65 547-557.
128. Poliovirus infections (1997) In Peter G, Hall C, Halsey N, et al. eds. Red Book Report of the Committee of Infectious Diseases, 24th edn Elk Grove IL: American Academy of Pediatrics 424-433.
129. H Bijkerk (1981) Poliomyelitis in the Netherlands. Dev Biol Stand 47 233-240.
130. H Bijkerk (1979) Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand 43 195-206.
131. PM Oostvogel, JK van Wijngaarden, HG van der Avoort, et al. (1994) Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–93 [see comments]. Lancet 344 665-670.
132. M Bottiger, P Mellin, V Romanus, et al. (1979) Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull World Health Organ 57 99-103.
133. CDC Epidemiological notes and reports follow-up on poliomyelitis—United States, Canada, Netherlands, 1979. MMWR 28 345.
134. CDC Lack of evidence for wild poliovirus circulation—United States, 1993. MMWR 43 957-959.
135. HC Rumke (1993) Vaccination against polio. Inactivated polio vaccine used in The Netherlands and Burkina Faso. Trop Geogr Med 45 202-205.
136. PM Oostvogel, HC Rumke, MA Conyn-Van Spaendonck, et al. (2001) Poliovirus circulation among schoolchildren during the early phase of the 1992–1993 poliomyelitis outbreak in The Netherlands. J Infect Dis 184 1451-1455.
137. H Faden, L Duffy, M Sun and C Shuff (1993) Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 168 452-454.
138. E Vidor, C Meschievitz and SA Plotkin (1997) Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 16 312-322.
139. M Bottiger (1990) Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 8 443-445.
140. TA Swartz, M Roumiantzeff, L Peyron, et al. (1986) Use of a combined DTP-polio vaccine in a reduced schedule. Dev Biol Stand 65 159-166.
141. J Salk, J Drucker and D Malvy (1994) Noninfectious poliovirus vaccine. S Plotkin, E Mortimer, Jr (Eds) Vaccines 2nd edn Philadelphia: W.B. Saunders 205-227.
142. J Taranger, B Trollfors, N Knutsson, et al. (1999) Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 18 884-891.
143. B Carlsson, BA Claesson, N Knutsson and C Lundin (2002) Antibody persistence in 5 year old children who received a pentavalent vaccine in infancy. Pediatr Infect Dis J In press
144. J Taranger, B Trollfors, N Knutsson, et al. (1999) Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 18 884-891.
145. RM Carlsson, BA Claesson, E Fagerlund, et al. (2002) Antibody persistence in 5 year old children who received a pentavalent vaccine in infancy. Pediatr Infect Dis J 21 535-541.
146. Langue J, Thebault C, Boisnard F, Blondeau C. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and haemophilus influenzae type B (Hib) in 5–6 years old children. 2001. Presented at th 19th annual meeting of ESPID, Istanbul, Turkey.
147. J Langue, N Matisse, P Pacoret, et al. (2004) Persistence of antibodies at 5–6 years of age for children who received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5–6 years of age. Vaccine 22 1406-1414.
148. E Mallet, N Matisse, N Mathieu, et al. (2004) Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6 year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 22 1415-1422.
149. J Salk (1960) Persistence of immunity after administration of formalin-treated poliovirus vaccine. Lancet 2 715-723.
150. J Salk (1990) Are booster doses of poliovirus vaccine necessary? Vaccine 8 419-420.
151. D Salk and ALSJ van Wezel (1984) Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 1317-1321.
152. F Abbink, AM Buisman, G Doornbos, et al. (2005) Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 191 990-999.
153. Pasteur Merieux Connaught Laboratories (Aventis Pasteur) Package insert. Poliovirus Vaccine Inactivated (IPOL), 1997.
154. WA Wattigney, GT Mootrey, MM Braun and RT Chen (2001) Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 107 E83.
155. Reinert P, Boucher J, Pines E, et al. Primary and booster immunization with DTaP-IPV vaccine administered either in combination or in association with a Haemophilus influenzae type b vaccine (Act-HIB): a large scale safety study. 15th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) Paris, 1997.
156. N Nathanson and AD Langmuir (1963) The Cutter Incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United states during the spring of 1955. I. Background. Amer J Hyg 78 16-28.
157. N Nathanson and AD Langmuir (1995) The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 142 109-140.
158. PA Offit (2005) The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis New Haven: Yale University Press
159. SA Plotkin (1995) Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 14 835-839.
160. JS Butel and JA Lednicky (1999) Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 91 119-134.
161. RA Vilchez, CR Madden, CA Kozinetz, et al. (2002) Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 359 817-823.
162. N Shivapurkar, K Harada, J Reddy, et al. (2002) Presence of simian virus 40 DNA sequences in human lymphomas. Lancet 359 851-852.
163. T Dang-Tan, SM Mahmud, R Puntoni and EL Franco (2004) Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23 6535-6540.
164. DL Poulin and JA De Caprio (2006) Is there a role for SV40 in human cancer. J Clin Oncol 24(26), 4356-4365.
165. A Schattner, E Ben Chetrit and H Schmilovitz (1992) Poliovaccines and the course of systemic lupus erythematosus–a retrospective study of 73 patients. Vaccine 10 98-100.
166. Committee on Infectious Diseases, American Academy Pediatrics Poliovirus Infections. Pickering, L.K. Redbook Report of the Committee on Infections Diseases 25th, 467–470, 2000
167. DR Prevots, RK Burr, RW Sutter and TV Murphy (2000) Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49 1-22.
168. SA Plotkin (1997) Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis. Rev Med Virol 7 75-81.
169. P Laroche, M Barrand, SC Wood, et al. (1999) The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV). Infection 27(1), 49-56.
170. JM Jacquet, P Begue, E Grimprel, et al. (2006) Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 24 2440-2448.
171. J Southern, N Andrews, M Burrage and E Miller (2005) Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 23 3829-3835.
172. RW Sutter and DR Prevots (1994) Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infections in Medicine June(426), 438.
173. M Bottiger (1993) The elimination of polio in the Scandinavian countries. Public Health Rev 21 27-33.
174. M Bottiger, P Mellin, V Romanus, et al. (1979) Epidemiological events surrounding a paralytic case of poliomyelitis in sweder. Bull World Health Oran 57 99-103.
175. T Hovi, K Cantell, A Huovilainen, et al. (1986) Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1 1427-1432.
176. K Lapinleimu (1984) Elimination of poliomyelitis in Finland. Rev Infect Dis 6(Suppl 2), S457–S460.
177. DI Magrath, DM Evans, M Ferguson, et al. (1986) Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. J Gen Virol 67(Pt 5), 899-905.
178. L Piirainen, M Stenvik, M Roivainen, et al. (1999) Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. Vaccine 17(9–10), 1084-1090.
179. H von Magnus and I Petersen (1984) Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 6(Suppl 2), S471-S474.
180. AL van Wezel, G van Steenis, MP van der and AD Osterhaus (1984) Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 6(Suppl 2), S335–S340.
181. MA Conyn-Van Spaendonck, HE de Melker, F Abbink, et al. (2001) Immunity to poliomyelitis in the Netherlands. Am J Epidemiol 153 207-214.
182. DJ Malvy and J Drucker (1993) Elimination of poliomyelitis in France: epidemiology and vaccine status. Public Health Rev 21 41-49.
183. C Roure, I Rebiere, M Aymard, et al. (1993) Surveillance de la poliomyelite en France. Bull epidemiol Hebd 15 59-61.
184. N Guerin, P Bregere, P Caudrelier and O Raynaud (1998) Neutralizing antibody response to oral poliovirus vaccine after primary immunization with inactivated poliovirus vaccine. Eur J Clin Microbiol Infect 17(11), 815-816.
185. J Drucker (1991) Poliomyelitis in France: epidemiology and vaccination status. Pediatr Infect Dis J 10 967-969.
186. Surveillance des enterovirus en France, 2001–2003. Réseau de surveillance des entérovirus (RSE), Centre national de référence (CNR) des entérovirus et Laboratoire d'hygiène de la ville de Paris. 2006.
187. Ministry of Health Ontario (1996) Wild-type poliovirus isolated in Hamilton. Public Health Epidemiol Rep 7 51-52.
188. ACIP Poliomyelitis prevention in the United States (1997) Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine-live attenuated poliovirus vaccine immunization schedules. MMWR 46 1-25.
189. PM Strebel, RW Sutter, SL Cochi, et al. (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14 568-579.
190. R Yogev and KM Edwards (1999) Polio vaccination schedules in the United States: the rationale for change. Sem Ped Infect Dis 10 249-257.
191. MS Kolasa, SN Desai, KM Bisgard, et al. (2000) Impact of the sequential poliovirus immunization schedule: a demonstration project. Am J Prev Med 18 140-145.
192. CN Lakhiani, PM Vivier, AJ Alario, et al. (2000) Analysis of the transition from oral polio vaccine to inactivated polio vaccine for primary immunization in a hospital-based primary care practice. Pediatr Infect Dis J 19 575-576.
193. TA Lieu, RL Davis, AM Capra, et al. (2001) Variation in clinician recommendations for multiple injections during adoption of inactivated polio vaccine. Pediatrics 107 E49.
194. RL Davis, TA Lieu, LK Mell, et al. (2001) Impact of the change in polio vaccination schedule on immunization coverage rates: a study in two large health maintenance organizations. Pediatrics 107 671-676.
195. Eskola J, Dagan AvP study PNF35, data in file. 2000
196. EE Lasch, Y Abed, K Abdulla, et al. (1984) Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 6 (Suppl 2), S467-S470.
197. TA Swartz, E Ben Porath, H Kanaaneh, et al. (1984) Comparison of inactivated poliovirus vaccine and oral poliovirus vaccine programs in Israel. Rev Infect Dis 6(Suppl 2), S556-S561.
198. N Linder, I Taushtein, R Handsher, et al. (1998) Placental transfer of maternal poliovirus antibodies in full-term and pre-term infants. Vaccine 16 236-239.
199. PE Slater, WA Orenstein, A Morag, et al. (1990) Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 335 1192-1195.
200. AW Tucker, D Isaacs and M Burgess (2001) Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust NZ J Public Health 25 411-416.
201. TJ John (1993) Immunisation against polioviruses in developing countries. Rev Med Virol 3 149-160.
202. HF Hull and RB Aylward (1997) Ending polio immunization [see comments]. Science 277 780.
203. TJ John (2001) Anomalous observations on IPV and OPV vaccination. Dev Biol (Basel) 105 197-208.
204. K Estevrs (1988) Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organization 66(6), 739-746.
205. TJ John (2004) A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull World Health Organ 82(1), 53-57.
206. AM McBean and JF Modlin (1987) Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 6 881-887.
207. HF Hull and RB Aylward (2001) Progress towards global polio eradication. Vaccine 19 4378-4384.
208. HF Hull, ME Birmingham, B Melgaard and JW Lee (1997) Progress toward global polio eradication. J Infect Dis 175(Suppl 1), S4-S9.
209. I Arita, M Nakane and F Fenner (2006) Public health: Is polio eradication realistic. Science 312(5775), 852-854.
210. RB Aylward, RW Sutter and DL Heymann (2005) Policy. OPV cessation–the final step to a ‘polio-free’ world. Science 310 625-626.
211. OM Kew, RW Sutter, EM de Gourville, et al. (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 59 587-635.
212. Progress toward poliomyelitis eradication–India, January 2004-May 2005. MMWR Morb Mortal Wkly Rep 54 655-659.
213. S Bonu, M Rani and TD Baker (2003) The impact of the national polio immunization campaign on levels and equity in immunization coverage: evidence from rural North India. Soc Sci Med 57 1807-1819.
214. A Phadke and A Kale (2004) The mirage of polio eradication. Natl Med J India 17 282.
215. DC Sharma (2003) Indian experts favour IPV to eradicate polio. Lancet 362 1292.
216. Vaccines and biologicals Report of the interim meeting of the technical consultative group (TCG) on the global eradication of poliomyelitis, Geneva, November 9–11, 2002. World Health Organization, Geneva, 2003.
217. Brief report (2005) Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication–Geneva, Switzerland, October 2005. MMWR Morb Mortal Wkly Rep 54 1186-1188.
218. DL Heymann, RW Sutter and RB Aylward (2005) A global call for new polio vaccines. Nature 434 699-700.
219. DA Henderson (2002) Countering the posteradication threat of smallpox and polio. Clin Infect Dis 34 79-83.
220. TJ John (2000) The final stages of the global eradication of polio. N Engl J Med 343 806-807.
221. JM Deshpande, SS Nadkarni and ZA Siddiqui (2003) Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res 118 217-223.
222. B Diamond (2005) Global polio campaign doomed to fail, experts warn. Nat Med 11 1260.
223. VI Agol, K Chumakov, E Ehrenfeld and E Wimmer (2005) Don't drop current vaccine until we have new ones. Nature 435 881.
224. MM Georgescu, F Delpeyroux, M Tardy-Panit, et al. (1994) High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 68 8089-8101.
225. AW Dove and VR Racaniello (1997) The polio eradication effort: should vaccine eradication be next? [see comments]. Science 277 779-780.
226. Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 46 641-643.
227. S Guillot, V Caro, N Cuervo, et al. (2000) Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 74 8434-8443.
228. O Kew, V Morris-Glasgow, M Landaverde, et al. (2002) Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296 356-359.
229. Prevention of poliomyelitis recommendations for use of only inactivated poliovirus vaccine for routine immunization. Committee on Infectious Diseases. American Academy of Pediatrics. Pediatrics 104 1404-1406.
230. VR Racaniello (2000) It is too early to stop polio vaccination. Bull World Health Organ 78 359-360.
231. BD Schoub (2000) The risks of stopping vaccination: perspectives from the developing world. Bull World Health Organ 78 360-361.
232. PE Fine (2000) Gaps in our knowledge about transmission of vaccine-derived polioviruses. Bull World Health Organ 78 358-359.
233. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 78 241-250.
234. TY Kimman and N Book (2006) The polio eradication effort has been a great success—let's finish it and replace it with something even better. Lancet Infect Dis 6(10), 675-678.